An optimal female reproductive tract (FRT) microbiome represents a cornerstone for successful reproductive and sexual health. Although understanding the link between the microbiota and our health is the focus of a growing number of research programs and research has advanced in the last decade, the FRT microbiome remains relatively poorly defined. This is despite it being one of the most critical factors impacting fertility and the health of the future generation.
Important gaps in our knowledge remain about women-specific microbial niches, such as the lower FRT. The vaginal microbiome of healthy women is almost exclusively dominated by Lactobacillus species, making these species synonymous with vaginal health. Largely thanks to their capacity to produce high levels of lactic acid, lactobacilli are thought to inhibit most invading bacterial and viral pathogens. Nonetheless, the dogma that all Lactobacillus species are key beneficial species in the vaginal niche has been questioned, based on the association with disease for some of the major players in the niche, for example L. iners, particularly in non-European or Caucasian cohorts. Further, the ability of other (mostly anaerobic) species besides lactobacilli, to maintain similar homeostasis in the vaginal niche raises the question of what we define as optimal or healthy vaginal microbiota.
Answering this question is essential since a non-optimal or dysbiotic vaginal microbiome has been linked to the acquisition of sexually transmitted infections (STIs), infertility, and adverse pregnancy outcomes. To confront these healthcare challenges we should be able to distinguish between an optimal and non-optimal microbiome. With the advance of sequence-based technologies, as well as other omics methodologies, including metaproteomics, metabolomics and culturomics, we are now able to begin to correlate the presence, as well as the activities, of specific organisms and microbial communities with health or disease. However, we are only beginning to understand the complexity of interactions between bacterial community members with each other and the human host. A better understanding of these relationships within this specialized environmental niche and in relation to female sexual and reproductive health is critical for the development of novel diagnostics and therapeutics to create and maintain an optimal FRT microbiome.
This Research Topic aims to explore novel insights to improve our understanding of the FRT microbiome and its role in sexual and reproductive health. We welcome original research articles, reviews, mini reviews, perspectives and brief research reports that explore and improve our understanding of the FRT microbiome. We welcome subtopics on but, but not limited to:
• What we consider healthy or optimal microbiota in the FRT?
• How do we define disease or non-optimal microbiota in the FRT?
• FRT microbiota and sexually transmitted infections.
• Interactions between the female reproductive microbiota and its host.
• In vitro and in vivo based techniques to understand the role of vaginal isolated species in host immunomodulation, viral and bacterial pathogen exclusion.
• Bacterial vaginosis and the importance of bacteria biofilms.
• Female reproductive microbiota during pregnancy and its role in pregnancy outcomes.
• Health-promoting properties of vaginally isolated Lactobacillus species.
• The use of probiotics, biotherapeutics, or bioactives in targeting the microbiome for the prevention and treatment of vaginally associated diseases.
Dr. Petrova is employed by Winclove Probiotics, and is the founder of Microbiome insights and Probiotics (MiP) Consultancy. The other Topic Editors declare no conflict of interest with regards to the Research Topic theme.
An optimal female reproductive tract (FRT) microbiome represents a cornerstone for successful reproductive and sexual health. Although understanding the link between the microbiota and our health is the focus of a growing number of research programs and research has advanced in the last decade, the FRT microbiome remains relatively poorly defined. This is despite it being one of the most critical factors impacting fertility and the health of the future generation.
Important gaps in our knowledge remain about women-specific microbial niches, such as the lower FRT. The vaginal microbiome of healthy women is almost exclusively dominated by Lactobacillus species, making these species synonymous with vaginal health. Largely thanks to their capacity to produce high levels of lactic acid, lactobacilli are thought to inhibit most invading bacterial and viral pathogens. Nonetheless, the dogma that all Lactobacillus species are key beneficial species in the vaginal niche has been questioned, based on the association with disease for some of the major players in the niche, for example L. iners, particularly in non-European or Caucasian cohorts. Further, the ability of other (mostly anaerobic) species besides lactobacilli, to maintain similar homeostasis in the vaginal niche raises the question of what we define as optimal or healthy vaginal microbiota.
Answering this question is essential since a non-optimal or dysbiotic vaginal microbiome has been linked to the acquisition of sexually transmitted infections (STIs), infertility, and adverse pregnancy outcomes. To confront these healthcare challenges we should be able to distinguish between an optimal and non-optimal microbiome. With the advance of sequence-based technologies, as well as other omics methodologies, including metaproteomics, metabolomics and culturomics, we are now able to begin to correlate the presence, as well as the activities, of specific organisms and microbial communities with health or disease. However, we are only beginning to understand the complexity of interactions between bacterial community members with each other and the human host. A better understanding of these relationships within this specialized environmental niche and in relation to female sexual and reproductive health is critical for the development of novel diagnostics and therapeutics to create and maintain an optimal FRT microbiome.
This Research Topic aims to explore novel insights to improve our understanding of the FRT microbiome and its role in sexual and reproductive health. We welcome original research articles, reviews, mini reviews, perspectives and brief research reports that explore and improve our understanding of the FRT microbiome. We welcome subtopics on but, but not limited to:
• What we consider healthy or optimal microbiota in the FRT?
• How do we define disease or non-optimal microbiota in the FRT?
• FRT microbiota and sexually transmitted infections.
• Interactions between the female reproductive microbiota and its host.
• In vitro and in vivo based techniques to understand the role of vaginal isolated species in host immunomodulation, viral and bacterial pathogen exclusion.
• Bacterial vaginosis and the importance of bacteria biofilms.
• Female reproductive microbiota during pregnancy and its role in pregnancy outcomes.
• Health-promoting properties of vaginally isolated Lactobacillus species.
• The use of probiotics, biotherapeutics, or bioactives in targeting the microbiome for the prevention and treatment of vaginally associated diseases.
Dr. Petrova is employed by Winclove Probiotics, and is the founder of Microbiome insights and Probiotics (MiP) Consultancy. The other Topic Editors declare no conflict of interest with regards to the Research Topic theme.
